Clinical Trial Update: A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Vigil in combination with irinotecan and temozolomide for Ewing sarcoma has been terminated; results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ewing Family of Tumors
• Ewing Sarcoma

Drugs mentioned

• Irinotecan (Irinotecan)
• Temozolomide (Temozolomide)
• Vigil

Snippet

Sponsor: Gradalis, Inc. | Conditions: Ewing Sarcoma, Ewing Family of Tumors | Phase 3 | Status: TERMINATED | Results posted: 2023-04-26